Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Lost Money on Humacyte, Inc.(HUMA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
Humacyte, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HUMA
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
Levi & Korsinsky Reminds Shareholders of an Investigation into Humacyte, Inc. (HUMA) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $5.82, indicating a +1.75% shift from the previous trading day.
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors
Humacyte, Inc. (HUMA) closed at $5.70 in the latest trading session, marking a +0.53% move from the prior day.
Humacyte, Inc. (HUMA) Increases Yet Falls Behind Market: What Investors Need to Know
Humacyte, Inc. (HUMA) closed at $5.46 in the latest trading session, marking a +0.09% move from the prior day.
Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
Humacyte's acellular tissue engineered vessel (ATEV) shows promise in trauma and dialysis, with positive clinical trial results and potential FDA approval by year-end. Despite FDA delays, Humacyte remains optimistic but faces financial instability, with only $43.6 million in cash, supporting operations for 1.5 quarters. HUMA stock is rated as a moderate "Buy" for high-risk tolerant investors, given the potential for FDA approval and significant market capture in trauma.
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Humacyte's (HUMA) ATEV BLA Review Period Extended by FDA
Humacyte's (HUMA) Biologic License Application for its ATEV faces a delay as the FDA extends its review timeline, recognizing the product's potential impact on vascular trauma treatment.
Humacyte, Inc. (HUMA) Q2 2024 Earnings Call Transcript
Humacyte, Inc. (NASDAQ:HUMA ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Lauren Marek - LifeSci Advisors Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen & Company Allison Bratzel - Piper Sandler Kristen Kluska - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Operator Good afternoon, ladies and gentlemen, and welcome to the Humacyte's Second Quarter Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review
Friday, the FDA announced it would require additional time to complete its review of Humacyte Inc.'s HUMA Biologic License Application (BLA) for the acellular tissue-engineered vessel (ATEV) in the vascular trauma indication.
US FDA extends review of Humacyte's blood vessel implant
Humacyte said on Friday the U.S. health regulator has extended review of the company's implant that can act as a replacement for an injured or damaged blood vessel, sending its shares down more than 20% after the bell.
